A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer
Kimberly Blackwell(Duke University), M. S. Berger(Duke University), Sandra Franco(Clínica Santa María), P. Kelly Marcom(Duke University), Eli Kaplan(Tel Aviv University), M. J. Sorensen(GlaxoSmithKline (United States)), Janet Maleski(GlaxoSmithKline (United States))
Cited by 90
Related Papers
Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
|Journal of Clinical Oncology|2010|960
Young Age at Diagnosis Correlates With Worse Prognosis and Defines a Subset of Breast Cancers With Shared Patterns of Gene Expression
|Journal of Clinical Oncology|2008|917
Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer
|Clinical Cancer Research|2013|744
Genetic/Familial High-Risk Assessment: Breast and Ovarian
|Journal of the National Comprehensive Cancer Network|2010|650